NASDAQ:ZLABZai Lab Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zai Lab Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $74.01 -0.39 (-0.52 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$73.17Now: $74.01▼$74.9550-Day Range$58.06MA: $65.70▼$74.4052-Week Range$26.01Now: $74.01▼$76.39Volume392,000 shsAverage Volume477,953 shsMarket Capitalization$4.30 billionP/E RatioN/ADividend YieldN/ABeta1.11 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.31, Zai Lab has a potential downside of 22.6% from its current price of $74.01.Amount of Analyst CoverageZai Lab has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesZai Lab has received 181 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZai Lab has received 210 “underperform” votes. (Add your “underperform” vote.)Community SentimentZai Lab has received 53.71% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote “Outperform” if you believe ZLAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have not sold or bought any company stock.Percentage Held by Institutions78.29% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($3.46) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -24.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -24.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 14.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.09 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZLAB Previous Symbol CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone86-21-6163-2588Debt Debt-to-Equity RatioN/A Current Ratio6.27 Quick Ratio6.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.98 million Price / Sales331.31 Cash FlowN/A Price / Cash FlowN/A Book Value$5.07 per share Price / Book14.60Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees309 Outstanding Shares58,105,000Market Cap$4.30 billion Next Earnings DateN/A OptionableOptionable NASDAQ:ZLAB Rates by TradingView Receive ZLAB News and Ratings via Email Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions How has Zai Lab's stock been impacted by COVID-19 (Coronavirus)? Zai Lab's stock was trading at $50.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZLAB shares have increased by 47.6% and is now trading at $74.01. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Zai Lab? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zai Lab. How were Zai Lab's earnings last quarter? Zai Lab Ltd (NASDAQ:ZLAB) issued its earnings results on Thursday, March, 19th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.05. The business earned $4.65 million during the quarter. View Zai Lab's earnings history. What price target have analysts set for ZLAB? 7 equities research analysts have issued 1 year price objectives for Zai Lab's stock. Their forecasts range from $36.54 to $84.00. On average, they anticipate Zai Lab's stock price to reach $57.31 in the next twelve months. This suggests that the stock has a possible downside of 22.6%. View analysts' price targets for Zai Lab. Has Zai Lab been receiving favorable news coverage? Media headlines about ZLAB stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zai Lab earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. View the latest news aboutZai Lab. Are investors shorting Zai Lab? Zai Lab saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 1,920,000 shares, a drop of 11.9% from the April 15th total of 2,180,000 shares. Based on an average daily volume of 507,200 shares, the short-interest ratio is currently 3.8 days. Approximately 3.5% of the company's shares are short sold. View Zai Lab's Current Options Chain. Who are some of Zai Lab's key competitors? Some companies that are related to Zai Lab include Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Mylan (MYL), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). View all competitors. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), InVitae (NVTA), Baozun (BZUN), Fulgent Genetics (FLGT), Intellia Therapeutics (NTLA), Beigene (BGNE), Marvell Technology Group (MRVL) and Niu Technologies (NIU). Who are Zai Lab's key executives? Zai Lab's management team includes the following people: Dr. Ying Du, Founder, Chairman & CEO (Age 53)Mr. Tao Fu, Pres, COO & Director (Age 47)Mr. Ki Chul Cho, Chief Financial Officer (Age 41)Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54) When did Zai Lab IPO? (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. What is Zai Lab's stock symbol? Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB." Who are Zai Lab's major shareholders? Zai Lab's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital World Investors (10.12%), Baillie Gifford & Co. (5.36%), Wellington Management Group LLP (4.73%), BlackRock Inc. (3.56%), Federated Hermes Inc. (3.42%) and Segantii Capital Management Ltd (3.13%). Which major investors are selling Zai Lab stock? ZLAB stock was sold by a variety of institutional investors in the last quarter, including Segantii Capital Management Ltd, Orbimed Advisors LLC, Wellington Management Group LLP, AXA, Greenwoods Asset Management Ltd, Wells Fargo & Company MN, Morgan Stanley, and Invesco Ltd.. Which major investors are buying Zai Lab stock? ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, BlackRock Inc., State Street Corp, Federated Hermes Inc., Vivo Capital LLC, Assenagon Asset Management S.A., Casdin Capital LLC, and Legal & General Group Plc. How do I buy shares of Zai Lab? Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zai Lab's stock price today? One share of ZLAB stock can currently be purchased for approximately $74.01. How big of a company is Zai Lab? Zai Lab has a market capitalization of $4.30 billion and generates $12.98 million in revenue each year. The company earns $-195,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Zai Lab employs 309 workers across the globe. What is Zai Lab's official website? The official website for Zai Lab is www.zailaboratory.com. How can I contact Zai Lab? Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
